Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy

Epilepsy and Behavior

Volumn 29, Issue 3, 2013, Pages 574-577

  Porter, Brenda E ^a   Jacobson, Catherine ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Cannabidiol; Dravet syndrome; Epilepsy; Intractable; Medically refractory seizures; Pediatric; Side effects; Treatment resistant

Indexed keywords

ANTICONVULSIVE AGENT; CANNABIDIOL ENRICHED CANNABIS; STIRIPENTOL; UNCLASSIFIED DRUG;

ADOLESCENT; AGGRESSION; ALERTNESS; ANTICONVULSANT THERAPY; ANXIETY; APPETITE; ARTICLE; ATONIC SEIZURE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL ARTICLE; CONFUSION; DROWSINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FACEBOOK; FATIGUE; FEMALE; GENERALIZED EPILEPSY; HEALTH SURVEY; HUMAN; INFANTILE SPASM; INSOMNIA; IRRITABILITY; LENNOX GASTAUT SYNDROME; MALE; MOOD; MYOCLONIC ASTATIC EPILEPSY; MYOCLONUS SEIZURE; NAUSEA; PARENT; SEIZURE; SELF STIMULATION; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; SLEEP; SOCIAL MEDIA; TONIC CLONIC SEIZURE; TREATMENT DURATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

CANNABIDIOL; DRAVET SYNDROME; EPILEPSY; INTRACTABLE; MEDICALLY REFRACTORY SEIZURES; PEDIATRIC; SIDE EFFECTS; TREATMENT-RESISTANT;

ADOLESCENT; ANTICONVULSANTS; CANNABIDIOL; CHILD; EPILEPSIES, MYOCLONIC; EPILEPSY; FEMALE; HEALTH SURVEYS; HUMANS; MALE; PARENTS;

EID: 84887809109     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.08.037     Document Type: Article

References (23)

1. Wheless J.W. Managing severe epilepsy syndromes of early childhood. J Child Neurol 2009, 24:24S-32S. [quiz 33S-26S].
2. McTague A., Cross J.H. Treatment of epileptic encephalopathies. CNS Drugs 2013, 27:175-184.
3. Mechoulam R., Shani A., Edery H., Grunfeld Y. Chemical basis of hashish activity. Science 1970, 169:611-612.
4. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009, 30:515-527.
5. Zuardi A.W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008, 30:271-280.
6. Meier M.H., Caspi A., Ambler A., Harrington H., Houts R., Keefe R.S., et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012, 109:E2657-E2664.
7. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009, 259:413-431.
8. Karler R., Turkanis S.A. Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 1980, 68:479-484.
9. Izquierdo I., Orsingher O.A., Berardi A.C. Effect of cannabidiol and of other cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia 1973, 28:95-102.
10. Izquierdo I., Tannhauser M. Letter: the effect of cannabidiol on maximal electroshock seizures in rats. J Pharm Pharmacol 1973, 25:916-917.
11. Cox B., ten Ham M., Loskota W.J., Lomax P. The anticonvulsant activity of cannabinoids in seizure sensitive gerbils. Proc West Pharmacol Soc 1975, 18:154-157.
12. Consroe P., Benedito M.A., Leite J.R., Carlini E.A., Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982, 83:293-298.
13. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010, 332:569-577.
14. Jones N.A., Glyn S.E., Akiyama S., Hill T.D., Hill A.J., Weston S.E., et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012, 21:344-352.
15. Mechoulam R., Carlini E.A. Toward drugs derived from cannabis. Die Naturwissenschaften 1978, 65:174-179.
16. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-185.
17. Ames F.R., Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1986, 69:14.
18. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G., et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009, 42:377-381.
19. Chiron C., Marchand M.C., Tran A., Rey E., d'Athis P., Vincent J., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356:1638-1642.
20. Wheless J.W. Intractable epilepsy: a survey of patients and caregivers. Epilepsy Behav. 2006, 8:756-764.
21. Bourgeois B.F. Initiating antiepileptic drug treatment and characteristics of drugs. Handb Clin Neurol 2013, 111:719-725.
22. Consroe P., Martin P., Eisenstein D. Anticonvulsant drug antagonism of delta9tetrahydrocannabinol-induced seizures in rabbits. Res Commun Chem Pathol Pharmacol 1977, 16:1-13.
23. Turkanis S.A., Karler R. Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat. Psychopharmacology 1981, 75:294-298.